Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134

Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4-blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with BRAFV600-mutant metastatic melanoma, leading to broad regulatory approval. Little prospective data exist to guide the choice of either initial therapy or treatment sequence in this population. This study was conducted to determine which initial treatment or treatment sequence … Continua a leggere

Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAF^V600 wild-type melanoma progressing on prior anti-programmed death-1 therapy

To evaluate the efficacy and safety of cobimetinib plus atezolizumab in the treatment of patients with advanced BRAF^V600 wild-type melanoma who had progressed on prior anti‒programmed death-1 (PD-1) therapy. This phase 1b, open-label, international multicentre study enrolled 3 cohorts. Herein, we report on patients in cohorts A and B who had progressed on prior anti‒PD-1 therapy. … Continua a leggere

Interferon Alfa-2b Adjuvant Therapy of High-Risk Resected Cutaneous Melanoma: The Eastern Cooperative Oncology Group Trial EST 1684

Interferon alfa-2b (IFN alpha-2b) exhibits antitumor activity in metastatic melanoma and on this basis has been evaluated as an adjuvant therapy following surgery for deep primary (T4) or regionally metastatic (N1) melanoma. A randomized controlled study of IFN alpha-2b (Schering-Plough, Kenilworth, NJ) administered at maximum-tolerated doses of 20 MU/m2/d intravenously (i.v.) for 1 month and 10 MU/m2 three times per week subcutaneously (SC) … Continua a leggere

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials

Neoadjuvant ipilimumab plus nivolumab has yielded high response rates in macroscopic stage III melanoma patients. These response rates translated to high short-term survival rates. However, data on long-term survival and disease recurrence are lacking. In OpACIN, 20 macroscopic stage III melanoma patients were randomized to ipilimumab 3 mg/kg plus nivolumab 1 mg/kg q3w four cycles adjuvant or split two cycles neoadjuvant and two adjuvant. …  Continua a leggere

Tumor Burden and Health-Related Quality of Life in Patients with Melanoma In-Transit Metastases

Few studies have investigated the health-related quality of life (HRQOL) in patients with melanoma in-transit metastases (ITM). The aim was to investigate the association between tumor burden and HRQOL, including disparities pertaining to sex and age, in treatment-naïve patients with ITM. Functional Assessment of Cancer Therapy-Melanoma (FACT-M) questionnaire was used to assess HRQOL Pairwise comparisons … Continua a leggere